Chris Nowers has joined London-based cell therapy company Cell Medica as CEO after moving from the Gilead-owned Kite Pharma where he was European head. He replaces Cell Medica founder Gregg Sando. The company has raised more than $130m to build its portfolio of CAR-T and TCR therapies which are still under development. In a statement, Cell’s chief executive officer Dr David Sinclair said: “Cellular Therapeutics is delighted that we have been able to secure this exciting new partnership with one of Europe’s leading biotech companies.
Chris Nowers has joined London-based cell therapy company Cell Medica as CEO after moving from the Gilead-owned Kite Pharma where he was European head. He replaces Cell Medica founder Gregg Sando. The company has raised more than $130m to build its portfolio of CAR-T and TCR therapies which are still under development. It has yet to file for approval, but said Nowers had considerable experience of commercialising oncology programs in particular with Bristol-Myers’ checkpoint inhibitors Opdivo and Yervoy.